{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:22Z","timestamp":1792512922828,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"11-12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>A military soldier sustained a blast injury in Afghanistan, resulting in amputations and hemipelvectomy. He developed New Delhi metallo-beta-lactamase-producing E. coli bacteremia, soft-tissue infection, and sacral osteomyelitis. These organisms are being increasingly discovered in different communities around the world. He was successfully treated with tigecycline and cefiderocol. Cefiderocol is a novel siderophore-based cephalosporine developed to treat serious infections, including those caused by carbapenem-resistant Enterobacterales.<\/jats:p>","DOI":"10.1093\/milmed\/usab350","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T04:51:29Z","timestamp":1630126289000},"page":"1241-1245","source":"Crossref","is-referenced-by-count":6,"title":["Carbapenem-Resistant Enterobacterales Infection After Massive Blast Injury: Use of Cefiderocol Based Combination Therapy"],"prefix":"10.1093","volume":"186","author":[{"given":"B.W","family":"Carney","sequence":"first","affiliation":[{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A","family":"Rizzo","sequence":"additional","affiliation":[{"name":"United States Army Institute of Surgical Research, San Antonio, TX 78234, USA"},{"name":"Uniformed Services University of Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"Alderete","sequence":"additional","affiliation":[{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"R","family":"Cindass","sequence":"additional","affiliation":[{"name":"United States Army Institute of Surgical Research, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E","family":"Markelz","sequence":"additional","affiliation":[{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L C","family":"Cancio","sequence":"additional","affiliation":[{"name":"Brooke Army Medical Center, San Antonio, TX 78234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"issue":"5","key":"2021110307363438400_R1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1473-3099(11)70059-7","article-title":"Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study","volume":"11","author":"Walsh","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"14","key":"2021110307363438400_R2","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.4103\/0366-6999.160566","article-title":"New Delhi metallo-\u03b2-lactamase-mediated carbapenem resistance: origin, diagnosis, treatment and public health concern","volume":"128","author":"Wei","year":"2015","journal-title":"Chin Med J"},{"key":"2021110307363438400_R3","doi-asserted-by":"crossref","first-page":"e01968","DOI":"10.1128\/AAC.01968-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2021110307363438400_R4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jiph.2013.06.006","article-title":"Prevalence of metallo-\u03b2-lactamase NDM-1-producing multi-drug resistant bacteria at two Pakistani hospitals and implications for public health","volume":"6","author":"Nahid","year":"2013","journal-title":"J Infect Public Health"},{"issue":"2","key":"2021110307363438400_R5","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-18","article-title":"NDM metallo-beta-lactamases and their bacterial producers in health care settings","volume":"32","author":"Wu","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"2021110307363438400_R6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/1389450116666151001105622","article-title":"B1-metallo-\u03b2-lactamases: where do we stand?","volume":"17","author":"Mojica","year":"2016","journal-title":"Curr Drug Targets"},{"issue":"12","key":"2021110307363438400_R7","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1128\/AAC.05108-11","article-title":"A novel variant, NDM-5, of the New Delhi metallo-\u03b2-lactamase in a multidrug-resistant Escherichia coli ST648 isolate recovered from a patient in the United Kingdom","volume":"55","author":"Hornsey","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110307363438400_R8","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00248","article-title":"Novel variant of New Delhi metallo-\u03b2-lactamase, NDM-20, in Escherichia coli","volume":"9","author":"Liu","year":"2018","journal-title":"Front Microbiol"},{"issue":"9","key":"2021110307363438400_R9","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1128\/AAC.02425-14","article-title":"Molecular epidemiology of NDM-1-producing Enterobacteriaceae and Acinetobacter baumannii isolates from Pakistan","volume":"58","author":"Sartor","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2021110307363438400_R10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14787210.2017.1410434","article-title":"Combination therapy for extensively-drug resistant gram-negative bacteria","volume":"15","author":"Karaiskos","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"2021110307363438400_R11","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1128\/AAC.02449-14","article-title":"In vitro and in vivo activities of tigecycline-coilstin combination therapies against carbapenem-resistant enterobacteriaceae","volume":"58","author":"Betts","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021110307363438400_R12","doi-asserted-by":"publisher","DOI":"10.3389\/pubh.2019.00151","article-title":"The \u201cold\u201d and the \u201cnew\u201d antibiotics for MDR gram-negative pathogens: for whom, when, and how","author":"Karaiskos","year":"2019","journal-title":"Front Public Health Rev"},{"key":"2021110307363438400_R13","article-title":"Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics","author":"Zmarlicka","year":"2015","journal-title":"Infect Drug Resist"},{"issue":"S7","key":"2021110307363438400_R14","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2021110307363438400_R15","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz123","article-title":"Plazomicin is active against metallo-\u03b2-lactamase-producing enterobacteriaceae","volume":"6","author":"Serio","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2021110307363438400_R16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2021110307363438400_R17","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Disease Society of America antimicrobial resistant treatment guidance: gram-negative bacterial infections","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/11-12\/1241\/41067568\/usab350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/11-12\/1241\/41067568\/usab350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T07:38:41Z","timestamp":1635925121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/11-12\/1241\/6358810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":17,"journal-issue":{"issue":"11-12","published-online":{"date-parts":[[2021,8,28]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usab350","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,28]]}}}